India Pharma Outlook Team | Wednesday, 01 April 2026
Indian pharmaceutical firms looking to benefit from the global biologics boom are facing major obstacles, as China's hold on biotech supply chains becomes even stronger.
Recent developments show that companies in China have obtained over half of multiple project agreements with US-based biotech firms, underscoring the competitive challenges Indian firms experience in this profitable sector.
Unlike the generics market, where India established a global name through affordability and volume, biologics demand higher-level research skills, sophisticated manufacturing setups, and expert personnel.
These elements considerably increase the barriers to entry and financial uncertainties for businesses trying to expand in this field. China's swift growth in biologics has been supported by robust government backing, quick regulatory approvals, and fast-tracked drug clearances.
In 2023, biologics made up around 42% of all new drug approvals in China, jumping from just 9% in 2015, and marking its rising significance in the worldwide biopharmaceutical arena. Even with the hurdles, analysts believe there is considerable long-term potential for Indian companies.
Also Read: EU Approved Sanofi's Rezurock for Chronic GVHD Treatment
According to IQVIA, nearly 118 biologics are projected to lose patent protection in the US from 2025 to 2034, leading to a $232 billion biosimilar market opportunity. Existing Indian biosimilar exports, currently at $0. 8 billion, could increase to $4. 2 billion by 2030 and may hit $35 billion by 2047.
To remain competitive, Indian firms will have to transition from focusing on cost to developing capabilities, prioritizing innovation, advanced therapies, and global market reach.
.jpg)
.jpg)
